United Therapeutics stock price steady following patent settlement with Actavis
February 16, 2018 at 15:11 PM EST
The product in dispute makes up about 10 percent of the company's sales.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.